catalyst · primary record
JNJ-101556143 + Placebo + Best Supportive Care
Phase readout · 2028-02-14 · Prostatic Neoplasms
| Company | Janssen Research & Development, LLC |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT07906717 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:47.785Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Janssen Research & Development, LLC:JNJ-101556143 + Placebo + Best Supportive Care:2028-02-14:P3 primary completion · NCT07906717
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.